ISDA

Deposition Date 2013-10-24

Release Date 2014-02-12

Last Version Date 2024-05-22

Entry Detail

PDB ID:

4NCG

Keywords:

Transferase/Inhhibitor, Hydrolase/Inhhibitor

Title:

Discovery of Doravirine, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses

Biological Source:

Source Organism:

Human immunodeficiency virus 1 (Taxon ID: 11706)

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.58 Å

R-Value Free:

0.25

R-Value Work:

0.21

R-Value Observed:

0.21

Space Group:

C 2 2 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Reverse transcriptase/ribonuclease H
Gene (Uniprot):gag-pol
Chain IDs:A
Chain Length:563
Number of Molecules:1
Biological Source:Human immunodeficiency virus 1

UniProt ID:P04585 Pfam ID:PF00078, PF06817, PF06815, PF00075

Protein Blast

Polymer Type:polypeptide(L)
Molecule:p51 RT
Gene (Uniprot):gag-pol
Chain IDs:B
Chain Length:443
Number of Molecules:1
Biological Source:Human immunodeficiency virus 1

UniProt ID:P04585 Pfam ID:PF00078, PF06817, PF06815, PF00075

Ligand Molecules

2KW

Primary Citation

Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.

Cote, B, Burch, J.D, Asante-Appiah, E, Bayly, C, Bedard, L, Blouin, M, Campeau, L.C, Cauchon, E, Chan, M, Chefson, A, Coulombe, N, Cromlish, W, Debnath, S, Deschenes, D, Dupont-Gaudet, K, Falgueyret, J.P, Forget, R, Gagne, S, Gauvreau, D, Girardin, M, Guiral, S, Langlois, E, Li, C.S, Nguyen, N, Papp, R, Plamondon, S, Roy, A, Roy, S, Seliniotakis, R, St-Onge, M, Ouellet, S, Tawa, P, Truchon, J.F, Vacca, J, Wrona, M, Yan, Y, Ducharme, Y.Show

Bioorg.Med.Chem.Lett. 24 917 922 (2014)

PMID: 24412110 DOI: 10.1016/j.bmcl.2013.12.070

Abstact

The optimization of a novel series of non-nucleoside reverse transcriptase inhibitors (NNRTI) led to the identification of pyridone 36. In cell cultures, this new NNRTI shows a superior potency profile against a range of wild type and clinically relevant, resistant mutant HIV viruses. The overall favorable preclinical pharmacokinetic profile of 36 led to the prediction of a once daily low dose regimen in human. NNRTI 36, now known as MK-1439, is currently in clinical development for the treatment of HIV infection.

Legend

Protein

Chemical

Disease

Primary Citation of related structures